Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A New Validated Patient-Completed Neuropathic Pain Screening Tool for Use in the Primary Care Setting
Headache and Pain
(-)
160
Authors/Disclosures
Philippe Beauchemin, MD Dr. Beauchemin has received personal compensation in the range of $0-$499 for serving as a Consultant for Novartis. Dr. Beauchemin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche Canada. Dr. Beauchemin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Beauchemin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen Canada. Dr. Beauchemin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pendopharm. Dr. Beauchemin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Beauchemin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Ali M. Al-Salahat, MBBS (Creighton University - Neurology Program) Dr. Al-Salahat has nothing to disclose.
No disclosure on file
No disclosure on file
Carissa C. Dioquino No disclosure on file
No disclosure on file
Raed Alroughani, MD, FÂ鶹´«Ã½Ó³»­ Dr. Alroughani has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen, AstraZeneca, Novartis, Merck, Roche, Sanofi. Dr. Alroughani has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for AstraZeneca, Biogen, Novartis, Merck, Roche, Sanofi.